ArticleTherapeutic advances in gastroenterology2025
Anti-reflux mucosectomy superior to argon plasma coagulation in managing Barrett's esophagus by improving lower esophageal sphincter pressure and cardiac sphincter valve function: a single-center, retrospective study.
Article in Therapeutic advances in gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Barrett's esophagus (BE) is a premalignant condition, caused principally by gastroesophageal reflux disease (GERD). Anti-reflux mucosectomy (ARMS) is an effective endoscopic treatment for GERD-related BE, utilizing scar tissue in the area of the esophagogastric junction, narrowing the gastric cardia. Thus, an anti-reflux barrier is formed, which obstructs the reflux of gastric contents into the esophagus. Objectives: Therefore, in this study, we investigated whether GERD-related BE improved post-ARMS by analyzing the changes in lower esophageal sphincter (LES) pressure, Hill's classification for GERD, and GERD-related questionnaires. Design: In this retrospective study, we observed whether ARMS was superior to argon plasma coagulation (APC) in the management of GERD disease-related BE. Methods: Ninety-five patients were grouped into two cohorts, with 43 and 52 in the ARMS and APC cohorts, respectively. Four GERD-related questionnaires were administered. The anxiety self-rating scale (SAS) and depression self-rating scale (SDS) were used for the psychological evaluation of both cohorts. Endoscopic manifestations of BE were observed, and Hill's classification for GERD was employed. Moreover, high-resolution esophageal manometry was performed to test esophageal motility. The follow-up period was 6 months post-treatment. Results: Greater statistically significant improvements in the four GERD-related questionnaires and SAS and SDS scores were observed post-ARMS than post-APC. Lesion residue was statistically significantly lower in the post-ARMS cohort. Six months post-treatment, proton pump inhibitor use was statistically significantly higher in the ARMS cohort. Moreover, Hill's classification grades and the LES pressure improved statistically significantly post-ARMS after this time interval. The operation time and hospitalization duration were statistically significantly longer in the ARMS cohort than in the APC cohort. However, incidence rates of adverse events were similar. Conclusion: ARMS is more effective than APC as an endoscopic focal mucosal resection procedure for GERD-related BE and is an optional treatment for both BE excision and GERD improvement.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.